**Supplementary Table 1: Sensitivity Analysis**

|  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| **Scenario** |  | | **Incremental cost per QALY gained** | | | | | |
| **Austrian costs** | | | |  | **Canadian costs** | | |
| **MC vs Usual Care** | **BMC vs Usual Care** | | **BMC vs MC** |  | **MC vs Usual Care** | **BMC vs Usual Care** | **BMC vs MC** |
| Base case | €3 746 | Dominant | | Dominant |  | $5 554 | Dominant | Dominant |
| Alternate transition probabilities – Delea(13) | €3 771 | Dominant | | Dominant |  | $5 629 | Dominant | Dominant |
| Alternate transition probabilities – Reitsma (16) | €988 | Dominant | | Dominant |  | $1 249 | Dominant | Dominant |
| Alternate transition probabilities – Gohler (15) | €16 830 | €9 708 | | Dominant |  | $26 494 | $15 227 | Dominant |
| Alternate utility values – Gohler (17) | €3 846 | Dominant | | Dominant |  | $5 703 | Dominant | Dominant |
| 18 month time horizon | Dominant | Dominant | | Dominant |  | Dominant | Dominant | Dominant |
| 5 year time horizon | €355 | Dominant | | Dominant |  | Dominant | Dominant | Dominant |
| 10 year time horizon | €3 233 | Dominant | | Dominant |  | $4 701 | Dominant | Dominant |
| No differences in beta- blocker post 18 months | €4 026 | Dominant | | Dominant |  | $6 047 | Dominant | Dominant |
| No differences in outcomes post 18 months | Dominant | Dominant | | Dominant |  | Dominant | Dominant | Dominant |
| *Discount rate 3%* | *€4 175* | *Dominant* | | *Dominant* |  | *$6,265* | *Dominant* | *Dominant* |
| *No discounting* | *€4 383* | *Dominant* | | *Dominant* |  | *$7,363* | *Dominant* | *Dominant* |
|  |  |  |  |  |  |  |  |  |